Search
lapatinib (Tykerb)
Indications:
- adjunct treatment of breast cancer
- used in combination with capecitabine [1]
Dosage:
- 1250 mg PO QD
Monitor:
- liver function tests (serum ALT, serum AST, serum bilirubin, serum alkaline phosphatase) baseline, then every 4-6 weeks & as clinically indicated [2]
Adverse effects:
1) somewhat difficult to assess given the patient popluation & other treatments
2) most common: diarrhea, dyspepsia, rash
3) hepatoxicity [2]
Mechanism of action:
1) small-molecule tyrosine kinase inhibitor of HER1 & HER2
2) antineoplastic activity in patients with HER2-positive metastatic breast cancer, including inflammatory breast cancer
Related
chemotherapy for breast cancer
General
small inhibitory antineoplastic agent (ib drug)
References
- Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG,
Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B,
Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD,
Stein S, Cameron D.
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
N Engl J Med. 2006 Dec 28;355(26):2733-43.
PMID: 17192538
- Prescriber's Letter 17(7): 2010
Recommended Lab Monitoring for Common Medications
Liver Function Test Scheduling
Detail-Document#: 260704
(subscription needed) http://www.prescribersletter.com